Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.

Diagnostic biomarkers are measures that detect or confirm the presence of a disease or identify individuals with a subtype of the disease. For Parkinson's disease, unlike other neurodegenerative diseases such as Alzheimer's disease and Creutzfeldt-Jakob disease, diagnostic biomarkers remain elusive as none are yet available or approved for clinical use. A biomarker to diagnose early or prodromal Parkinson's disease with high accuracy would significantly enhance clinical practice as well as advance clinical therapeutic trials. Multiple lines of evidence support a role of α-synuclein in the pathophysiology of Parkinson's disease and hence major ongoing efforts to identify biomarkers for Parkinson's disease are aimed at measuring α-synuclein in peripheral tissues and biofluids, including cerebrospinal fluid. This work is still in the early stages of biomarker development and has been accompanied by both losses and victories. Here, α-synuclein in cerebrospinal fluid as a diagnostic marker for Parkinson's disease is reviewed, including measures of total α-synuclein, oligomeric and phosphorylated α-synuclein, and seeding activity of α-synuclein.

• Publication year

  2019

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2019-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2018.11.016PMID 30466800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

  2018cited by this paper
• Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)

  2018cited by this paper
• Prion protein amplification techniques.

  2018cited by this paper
• α-Synuclein and Parkinsonism: Updates and Future Perspectives

  2017cited by this paper
• Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

  2017cited by this paper
• Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC

  2017cited by this paper
• A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations

  2017cited by this paper
• Alzheimer disease: CSF biomarkers for Alzheimer disease — approaching consensus

  2017cited by this paper
• Animal models of α-synucleinopathy for Parkinson disease drug development

  2017cited by this paper
• Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis

  2017cited by this paper
• Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid

  2017cited by this paper
• The NINDS Parkinson's disease biomarkers program

  2016cited by this paper
• Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies

  2016cited by this paper
• Biomarkers in Lysosomal Storage Diseases

  2016cited by this paper
• Advanced tests for early and accurate diagnosis of Creutzfeldt–Jakob disease

  2016cited by this paper
• Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

  2016cited by this paper
• Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

  2015cited by this paper
• Parkinson's disease

  2015cited by this paper
• Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

  2015cited by this paper
• Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.

  2015cited by this paper
• Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

  2015cited by this paper
• Parkinson disease with REM sleep behavior disorder

  2015cited by this paper
• Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

  2014cited by this paper
• Prions in the urine of patients with variant Creutzfeldt-Jakob disease.

  2014cited by this paper
• Unbiased approaches to biomarker discovery in neurodegenerative diseases.

  2014cited by this paper
• Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease

  2014cited by this paper
• A test for Creutzfeldt-Jakob disease using nasal brushings.

  2014cited by this paper
• Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

  2014cited by this paper
• α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system

  2012cited by this paper
• Phosphorylated α-Synuclein in Parkinson’s Disease

  2012cited by this paper
• Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.

  2011cited by this paper
• Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion

  2011cited by this paper
• Risk Prediction in Cardiovascular Medicine Evaluating the Clinical Utility of a Biomarker A Review of Methods for Estimating Health Impact

  2011cited by this paper
• Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

  2010cited by this paper
• Rapid End-Point Quantitation of Prion Seeding Activity with Sensitivity Comparable to Bioassays

  2010cited by this paper
• Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

  2010cited by this paper
• Biopsies of olfactory epithelium in patients with Parkinson's disease

  2009cited by this paper
• Is Parkinson's disease a prion disorder?

  2009cited by this paper
• Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein

  2007cited by this paper
• Diagnostic tests 4: likelihood ratios

  2004cited by this paper
• Response: event-related brain dynamics -- unifying brain electrophysiology.

  2002cited by this paper
• Cyclic amplification of protein misfolding: application to prion-related disorders and beyond.

  2002cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Statistics Notes: Diagnostic tests 1: sensitivity and specificity

  1994cited by this paper

• A bibliometric analysis of alpha-synuclein in Parkinson’s disease from 2015 to 2024

  2026cites this paper
• Analysis of Single Particles of Amyloid Beta and α-Synuclein With Seeded Amplification for the Diagnosis of Alzheimer's and Parkinson's Disease.

  2025cites this paper
• Evaluation of non-motor symptoms in Parkinson’s disease using multiparametric MRI with the multiplex sequence

  2025cites this paper
• The function of previously unappreciated exerkines secreted by muscle in regulation of neurodegenerative diseases

  2024cites this paper
• Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis

  2024cites this paper
• An innovative method for the detection of alpha synuclein, a potential biomarker of Parkinson's disease: quartz tuning fork-based mass sensitive immunosensor design.

  2024cites this paper
• Decreased levels of phosphorylated synuclein in plasma are correlated with poststroke cognitive impairment

  2024cites this paper
• A Rapid, Sensitive, and Specific Detection of Aggregated α-Synuclein by a Liposome-Immobilized Cantilever Sensor

  2023cites this paper
• Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma α-Synuclein and Parkinson’s Disease

  2023cites this paper
• α-Synuclein in Parkinson's disease and advances in detection.

  2022cites this paper
• Application of α-Syn Real-Time Quaking-Induced Conversion for Brain and Skin Specimens of the Chinese Patients With Parkinson’s Disease

  2022cites this paper
• Premotor Parkinson's disease: Overview of clinical symptoms and current diagnostic methods.

  2021cites this paper
• Alpha-Synuclein: Biomarker for Parkinson’s Disease, It’s Estimation Methods, and Targeted Medicinal Therapies

  2021cites this paper
• Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies

  2021cites this paper
• White Matter Abnormalities in Patients With Parkinson's Disease: A Meta-Analysis of Diffusion Tensor Imaging Using Tract-Based Spatial Statistics

  2021cites this paper
• Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021; 165:XX

  2021cites this paper
• Evaluating the severity of 6-hydroxydopamine induced Parkinson ’ s disease in diabetic rats Prepared by Heba Jaber Subhi Ubied Supervised

  2020cites this paper
• The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

  2020cites this paper
• Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy

  2020cites this paper
• Parkinson’s disease: etiopathogenesis and treatment

  2020cites this paper
• Pharmacological targeting of α‐synuclein and TPPP/p25 in Parkinson's disease: challenges and opportunities in a Nutshell

  2019cites this paper
• Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview.

  2019cites this paper
• Prion Properties of Alpha-Synuclein

  2019influential citation